Camp Nine Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Camp Nine Inc
TickerRLMD
CIK #0001553643
CUSIP75955J402
SectorManufacturing - Sporting & Athletic Goods, Nec
Address1065 Kawaiahao St, Ste 2207, Honolulu, HI 96814
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Relmada Therapeutics Inc 2019-10-08 0.8 M Exemption: 506(b) · Minimum: $10,000 · Duration: One year or less · Revenue: No Revenues
Camp Nine Inc 2014-06-19 10.7 M Exemption: 506(b) · Minimum: $100,000 · Duration: One year or less · Commission: $1,069,458 · Revenue: No Revenues
CIK Filing 2011 - 2026
[0001553643] 10-K
[0001553643] 10-Q
[0001553643] 3
[0001553643] 4
[0001553643] 5
[0001553643] 8-K
[0001553643] D
[0001553643] SC 13D
[0001553643] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Millennium Management LLC Relmada Therapeutics Inc [2026-06-22] 0.0
Venrock Healthcare Capital Partners III LP Relmada Therapeutics Inc [2026-06-09] 0.0
Commodore Capital LP Relmada Therapeutics Inc [2026-05-04] 0.0
Spruce Street Capital LP Relmada Therapeutics Inc [2026-02-17] 0.0
Adage Capital Management LP Relmada Therapeutics Inc [2026-02-12] 0.0
Janus Henderson Group PLC Relmada Therapeutics Inc [2026-02-06] 0.0
Ikarian Capital LLC Relmada Therapeutics Inc [2025-11-14] 0.0
Squadron Capital Management LLC Relmada Therapeutics Inc [2025-05-01] 0.0
Vanguard Group Inc Relmada Therapeutics Inc [2023-02-09] 5.04
Kotler Kevin Relmada Therapeutics Inc [2022-12-20] 6.3
Deep Track Capital LP Relmada Therapeutics Inc [2022-10-21] 8.25
Point72 Asset Management LP Relmada Therapeutics Inc [2022-10-17] 7.3
Citadel Advisors LLC Relmada Therapeutics Inc [2022-10-17] 1.6
Perceptive Advisors LLC Relmada Therapeutics Inc [2022-09-23] 7.0
Venrock Healthcare Capital Partners II LP Relmada Therapeutics Inc [2022-02-14] 8.2
Biotechnology Value Fund L P Relmada Therapeutics Inc [2021-12-20] 3.0
RA Capital Management LP Relmada Therapeutics Inc [2021-12-20] 7.2
Avoro Capital Advisors LLC Relmada Therapeutics Inc [2021-02-12] 0.4
BlackRock Inc Relmada Therapeutics Inc [2021-02-02] 9.2
RTW Investments LP Relmada Therapeutics Inc [2020-06-11] 8.26
RA Capital Management LP Relmada Therapeutics Inc [2020-02-14] 5.4
Venrock Healthcare Capital Partners II LP Relmada Therapeutics Inc [2019-12-16] 6.2
Tang Capital Partners LP Relmada Therapeutics Inc [2019-10-31] 7.8
Wonpung Mulsan Co Ltd Relmada Therapeutics Inc [2019-04-05] 5.95
Kemmerer John L III Relmada Therapeutics Inc [2017-10-31] 8.7
Conway Bruce C Relmada Therapeutics Inc [2017-10-11] 10.7
UH EUN Sun Relmada Therapeutics Inc [2016-11-23] 8.57
Wonpung Mulsan Co Ltd Relmada Therapeutics Inc [2016-06-24] 6.06
Laidlaw & Company UK Ltd Relmada Therapeutics Inc [2015-10-22] 0.0
Honig Barry C Camp Nine Inc [2014-07-01] 9.99
Form 3/4/5 Filer 2011 - 2026
Relmada Therapeutics Inc
Casamento Charles J
Traversa Sergio
Shenouda Maged
Ence Chuck
Fedeli Fabiana
Glasspool John
Kelly Paul Edward
Schmidt Eric Thomas
O'Gorman Cedric
Wessel Thomas
Vitolo Ottavio V
Agharkar Shreeram
Nolan Lisa
Seth Sandesh
Salinas Eliseo Oreste
Beck Douglas
Yazgi Nabil
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Traversa Sergio
Common Stock
2025-12-15 Buy 27,500 $4.12 113,300
Shenouda Maged
Common Stock
2025-12-15 Buy 11,665 $4.12 48,060
Casamento Charles J
Stock Appreciation Rights · derivative
2025-12-12 Grant 164,000 $0.00
Traversa Sergio
Stock Appreciation Rights · derivative
2025-12-12 Grant 1,198,000 $0.00
Shenouda Maged
Stock Appreciation Rights · derivative
2025-12-12 Grant 828,000 $0.00
Ence Chuck
Stock Appreciation Rights · derivative
2025-12-12 Grant 828,000 $0.00
Glasspool John
Stock Appreciation Rights · derivative
2025-12-12 Grant 164,000 $0.00
Fedeli Fabiana
Stock Appreciation Rights · derivative
2025-12-12 Grant 164,000 $0.00
Kelly Paul Edward
Stock Appreciation Rights · derivative
2025-12-12 Grant 828,000 $0.00
Ence Chuck
Common Stock
2025-11-05 Buy 136,000 $2.20 299,200
Traversa Sergio
Common Stock
2025-11-05 Buy 272,500 $2.20 599,500
Shenouda Maged
Common Stock
2025-11-05 Buy 500,000 $2.20 1,100,000
Kelly Paul Edward
Common Stock
2025-11-05 Buy 90,000 $2.20 198,000
Common Stock
2025-08-28 Buy 55,976 $0.74 41,422
Common Stock
2025-08-27 Buy 129,455 $0.67 86,735
Common Stock
2025-08-26 Buy 80,545 $0.62 49,938
Traversa Sergio
Stock Option (right to buy) · derivative
2025-06-26 Grant 800,000 $0.00
Glasspool John
Stock Option (right to buy) · derivative
2025-06-26 Grant 100,000 $0.00
Fedeli Fabiana
Stock Option (right to buy) · derivative
2025-06-26 Grant 100,000 $0.00
Kelly Paul Edward
Stock Option (right to buy) · derivative
2025-06-26 Grant 400,000 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 104 84,994,128
2025-12-31 79 51,453,037
2025-09-30 45 7,823,881
2025-06-30 51 5,303,155
2025-03-31 45 6,219,493
2024-12-31 52 8,809,626
2024-09-30 72 11,872,979
2024-06-30 81 12,845,442
2024-03-31 94 13,659,019
2023-12-31 84 12,639,649
2023-09-30 89 13,939,597
2023-06-30 97 15,121,979
Form 13F Holdings
Firm Period DFND Voting Shares
MassMutual Private Wealth & Trust FSB [2026-06-30] SOLE 525 525
Gamma Investing LLC [2026-06-30] DFND 41 41
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com